Fair Value of Financial Instruments - Schedule of Inputs and Valuation Methodologies Used (Details) - Level 3 - Elusys Therapeutics - Discounted cash flow analysis	Mar. 31, 2024 Y USD ($)	Dec. 31, 2023 USD ($) Y
Contingent consideration receivable, related party | Maturity term
Fair Value of Financial Instruments
Contingent Consideration | Y		1
Contingent consideration receivable, related party | Market interest rate
Fair Value of Financial Instruments
Contingent Consideration		0.147
Contingent consideration receivable, related party | Principal amount
Fair Value of Financial Instruments
Contingent Consideration		2,250,000
Consideration earn-out receivable, related party | Discount rate
Fair Value of Financial Instruments
Contingent Consideration		0.150
Consideration earn-out receivable, related party | Future revenue projections
Fair Value of Financial Instruments
Contingent Consideration	153,200,000	141,400,000
Consideration earn-out receivable, related party | Minimum earn-out payment rate
Fair Value of Financial Instruments
Contingent Consideration	3
Consideration earn-out receivable, related party | Minimum earn-out payment
Fair Value of Financial Instruments
Contingent Consideration	5,000,000	5,000,000.0
Revenue earn-out | Discount rate
Fair Value of Financial Instruments
Contingent Consideration	0.150
Convertible Promissory Notes, Related Party | Market interest rate
Fair Value of Financial Instruments
Contingent Consideration	0.138
Convertible Promissory Notes, Related Party | Principal amount
Fair Value of Financial Instruments
Contingent Consideration	2,250,000
Convertible Promissory Notes, Related Party | Timing of expected payments
Fair Value of Financial Instruments
Contingent Consideration | Y	1.4
Minimum | Consideration earn-out receivable, related party | Minimum earn-out payment rate
Fair Value of Financial Instruments
Contingent Consideration		0.03